Calithera Biosciences - CALA Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares.
View CALA analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price objectives for Calithera Biosciences' shares. Their CALA share price forecasts range from $8.00 to $30.00. On average, they anticipate the company's stock price to reach $18.67 in the next year. This suggests a possible upside of 5,012.8% from the stock's current price.
View analysts price targets for CALA or view top-rated stocks among Wall Street analysts.

Calithera Biosciences' stock was trading at $3.26 at the start of the year. Since then, CALA stock has decreased by 88.8% and is now trading at $0.3651.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CALA earnings forecast.

Calithera Biosciences, Inc. (NASDAQ:CALA) released its earnings results on Monday, November, 14th. The biotechnology company reported ($2.01) earnings per share for the quarter, missing analysts' consensus estimates of ($1.99) by $0.02.

Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bvf Partners L P/Il, Deepika Pakianathan, Keith Orford, Stephanie Wong and Susan Molineaux.
View institutional ownership trends.

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CALA stock can currently be purchased for approximately $0.37.

Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $1.78 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115,090,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.